Bamco Inc. NY Acquires New Shares in Alnylam Pharmaceuticals, Inc. $ALNY

Bamco Inc. NY bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,500 shares of the biopharmaceutical company’s stock, valued at approximately $1,596,000.

Several other institutional investors have also recently bought and sold shares of ALNY. Root Financial Partners LLC acquired a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $25,000. Salomon & Ludwin LLC acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter worth $27,000. Ameriflex Group Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter worth $32,000. ORG Partners LLC lifted its stake in shares of Alnylam Pharmaceuticals by 70.2% in the 3rd quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 33 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $36,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 1.8%

Alnylam Pharmaceuticals stock opened at $318.91 on Tuesday. The company has a market capitalization of $42.29 billion, a PE ratio of 186.50 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55. The firm’s fifty day moving average is $342.78 and its 200 day moving average is $408.50. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. During the same quarter in the previous year, the business posted ($0.65) earnings per share. The company’s revenue for the quarter was up 84.9% compared to the same quarter last year. As a group, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the firm’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $370.33, for a total value of $848,055.70. Following the completion of the sale, the executive vice president owned 21,264 shares of the company’s stock, valued at approximately $7,874,697.12. This trade represents a 9.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Pushkal Garg sold 2,242 shares of the business’s stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $310.08, for a total value of $695,199.36. Following the sale, the executive vice president owned 24,848 shares of the company’s stock, valued at approximately $7,704,867.84. This represents a 8.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 53,923 shares of company stock worth $18,072,087 in the last three months. Insiders own 1.20% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ALNY shares. HC Wainwright restated a “buy” rating and set a $510.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 18th. Freedom Capital upgraded Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 17th. Oppenheimer began coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price target on the stock. Morgan Stanley reduced their price target on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a report on Friday, January 30th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and issued a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $468.84.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.